Cell Morphological Profiling Enables High-Throughput Screening for PROteolysis TArgeting Chimera (PROTAC) Phenotypic Signature
Citations Over TimeTop 10% of 2022 papers
Abstract
PROteolysis TArgeting Chimeras (PROTACs) use the ubiquitin-proteasome system to degrade a protein of interest for therapeutic benefit. Advances made in targeted protein degradation technology have been remarkable, with several molecules having moved into clinical studies. However, robust routes to assess and better understand the safety risks of PROTACs need to be identified, which is an essential step toward delivering efficacious and safe compounds to patients. In this work, we used Cell Painting, an unbiased high-content imaging method, to identify phenotypic signatures of PROTACs. Chemical clustering and model prediction allowed the identification of a mitotoxicity signature that could not be expected by screening the individual PROTAC components. The data highlighted the benefit of unbiased phenotypic methods for identifying toxic signatures and the potential to impact drug design.
Related Papers
- → Chimera and other fertilization errors(2006)107 cited
- → Analysis and Control of Proteolysis of Recombinant Proteins in Escherichia coli(2004)60 cited
- → An interspecies barrier to tetraploid complementation and chimera formation(2018)38 cited
- Proteolysis in alfalfa silage and its inhibiting method(2005)
- Progress on Proteolysis in Bacterial Cells(2008)